Corporate Overview

​

SynapCon GmbH is a Germany-based technology company operating a regulatory-grade digital infrastructure platform for global medical research.

Registered Office: Germany
Management:
Sven Engel – Chief Executive Officer
Ludwig Lutter – Chief Financial Officer

Marcus Orton - Chief Operations Officer

The Company delivers scalable cloud-based infrastructure supporting the full lifecycle of regulated medical research.

​

Public Funding & Innovation Support

​

SynapCon participates in German and European innovation frameworks supporting research and technology development.

​

German R&D Tax Incentive ("Forschungszulage")

​

The Company benefits from the German R&D tax incentive scheme, which provides refundable support for eligible research and development activities in accordance with applicable legislation.

The incentive may be refundable where no corresponding tax liabilities exist, subject to statutory conditions.

Further information available upon request.

​

Information for German Investors – BAFA Programmes

​

Eligible German investors may, under certain conditions, benefit from public investment support programmes (including BAFA related schemes), subject to individual qualification criteria and programme requirements.

Eligibility depends on:

• Investor status

• Investment structure

• Program availability

• Regulatory compliance

SynapCon does not provide tax or funding advice. Investors are encouraged to consult their advisor.

​

Awards & Recognition

​

SynapCon has received international recognition for innovation and clinical research technology, including:

• Best Clinical Trial Management System (multiple years)

• Best of Technology Award by WirtschaftsWoche & Handelsblatt

• Vendor qualification under recognized validation frameworks

• Government-supported innovation projects

These recognition reflect technological innovation, operational maturity, and regulatory competence.

​

Download Center

​

The following materials are available for qualified investors upon request:

• Corporate Presentation

• Executive Summary

• Infrastructure & Architecture Overview

• Regulatory Compliance Framework

• Capital Structure Summary

• Strategic Roadmap

Access to selected materials may be provided under NDA.

For requests:
invest@synapcon.com

​

Capital Strategy & Exit Perspective

​

SynapCon is positioned for long-term value creation through scalable infrastructure expansion and strategic partnerships.

Strategic horizon: 2030 / 2031

Potential pathways include:

• Strategic acquisition by infrastructure or healthcare technology groups

• Growth-stage private equity participation

• Public market optionality

The Company’s infrastructure positioning, regulatory depth, and AI integration roadmap support long-term enterprise relevance and valuation expansion.

Investor FAQ

​

What is SynapCon’s business model?

​

A recurring subscription-based digital infrastructure model serving regulated medical research environments.

​

What differentiates SynapCon from traditional SaaS providers?

​

SynapCon operates as regulatory-grade research infrastructure, integrating compliance, security, and AI-enabled automation across the full value chain.

​

Is the Company revenue-generating?

​

Yes. SynapCon operates a recurring subscription model and supports global clinical studies.

​

What is the long-term strategic objective?

​

Global expansion of secure medical research infrastructure and positioning for strategic exit optionality within the 2030 / 2031 horizon.

​

Are institutional allocations available?

​

Yes. Direct participation and strategic alignment discussions are available upon request.

​

Confidential discussions under NDA.

​